We confirmed that CAR-T cells with a dual HPA bridge exhibited superior tumor-killing and extended survival compared to CAR-T cells with the control CD19-bridge (Fig. 5p–r and Supplementary Fig. 6e). Here, CD19 is linked to neoplasm.